JP2011517673A5 - - Google Patents

Download PDF

Info

Publication number
JP2011517673A5
JP2011517673A5 JP2011501963A JP2011501963A JP2011517673A5 JP 2011517673 A5 JP2011517673 A5 JP 2011517673A5 JP 2011501963 A JP2011501963 A JP 2011501963A JP 2011501963 A JP2011501963 A JP 2011501963A JP 2011517673 A5 JP2011517673 A5 JP 2011517673A5
Authority
JP
Japan
Prior art keywords
hcv
inhibitor
hydrogen
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011501963A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011517673A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/038010 external-priority patent/WO2009120650A1/en
Publication of JP2011517673A publication Critical patent/JP2011517673A/ja
Publication of JP2011517673A5 publication Critical patent/JP2011517673A5/ja
Pending legal-status Critical Current

Links

JP2011501963A 2008-03-27 2009-03-24 芳香族ヘテロ環縮合インドロベンザジアゼピンhcvns5b阻害剤 Pending JP2011517673A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3996108P 2008-03-27 2008-03-27
US61/039,961 2008-03-27
PCT/US2009/038010 WO2009120650A1 (en) 2008-03-27 2009-03-24 Aromatic heterocyclic fused indolobenzadiazepine hcv ns5b inhibitors

Publications (2)

Publication Number Publication Date
JP2011517673A JP2011517673A (ja) 2011-06-16
JP2011517673A5 true JP2011517673A5 (enExample) 2012-05-10

Family

ID=40810527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011501963A Pending JP2011517673A (ja) 2008-03-27 2009-03-24 芳香族ヘテロ環縮合インドロベンザジアゼピンhcvns5b阻害剤

Country Status (10)

Country Link
US (1) US8431568B2 (enExample)
EP (1) EP2278977B1 (enExample)
JP (1) JP2011517673A (enExample)
KR (1) KR20100124848A (enExample)
CN (1) CN101980711B (enExample)
AT (1) ATE531373T1 (enExample)
AU (1) AU2009228451A1 (enExample)
ES (1) ES2374870T3 (enExample)
MX (1) MX2010010060A (enExample)
WO (1) WO2009120650A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103288828A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-6H-吲哚并[2,1-c][1,4]-苯并二氮杂卓的方法
CN103539723A (zh) * 2013-10-29 2014-01-29 南方医科大学 一种3-氨基-2-芳甲酰基-1h-吲哚类衍生物的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897392A (en) * 1989-07-03 1990-01-30 Hoechst-Roussel Pharmaceuticals, Inc. 4H-indolo(1,2-d)(1,2,4)triazolo(4,3-A)(1,4)benzodiazepines
DE602005013922D1 (de) * 2004-02-24 2009-05-28 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
AU2005298403A1 (en) 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) * 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) * 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7521442B2 (en) 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN101490054B (zh) 2006-05-25 2012-05-16 百时美施贵宝公司 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
KR20090029827A (ko) * 2006-07-20 2009-03-23 제네랩스 테크놀로지스, 인코포레이티드 폴리사이클릭 바이러스 억제제
US7642251B2 (en) 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8138171B2 (en) 2008-03-27 2012-03-20 Bristol-Myers Squibb Company Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors
US8133884B2 (en) 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Similar Documents

Publication Publication Date Title
JP2010515752A5 (enExample)
JP2010521481A5 (enExample)
JP2010521476A5 (enExample)
JP2010521484A5 (enExample)
JP2010521482A5 (enExample)
JP2010521483A5 (enExample)
JP2012504632A5 (enExample)
JP2013521279A5 (enExample)
HRP20110194T1 (hr) Ciklopropil fuzionirani indolobenzazepini kao inhibitori hcv ns5b
JP2013514359A5 (enExample)
JP2012512169A5 (enExample)
WO2005077969A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005007681A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
DE602004023924D1 (en) Ease-hemmer
WO2004113365A3 (en) Hepatitis c serine protease tri-peptide inhibitors
JP2012513479A5 (enExample)
JP2012528161A5 (enExample)
MX2010006210A (es) Inhibidores de serina proteasa de hcv de tripeptido fluorado.
WO2005037860A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
JP2011523651A5 (enExample)
JP2010532352A5 (enExample)
WO2008002924A3 (en) Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
JP2012504132A5 (enExample)
WO2009053828A3 (en) P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors